The management of obesity in type 2 diabetes mellitus

Current Medical Research and Opinion

Volumn 18, Issue SUPPL. 1, 2002, Pages

  Valsamakis, G ^a   Chetty, R K ^a   Kumar, S ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Bariatric surgery; Obesity; Orlistat; Sibutramine; Type 2 diabetes

Indexed keywords

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK FACTOR; UNITED KINGDOM; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; GREAT BRITAIN; HUMANS; OBESITY; RISK FACTORS; WEIGHT LOSS;

EID: 0036362993     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/030079902125000255     Document Type: Article

References (34)

1. Kopelman PG, Stock MJ. Epidemiology: definition and classification of obesity. In Kopelman PG, ed. Clinical Obesity, Oxford: Blackwell Science, 1998
2. Prescott-Clarke P, Primatesta P. Health Survey for England 1996. London: HMSO, 1998
3. WHO Study Group (1994) Prevention of Diabetes Mellitus. WHO technical report series; 844
4. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339-52
5. Sjostrom L, Larsson B, Backman L, et al. Swedish obese subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. Int J Obes Relat Metab Disord 1992;16:465-79
6. Sjostrom C, Lissner L, Sjostrom L. Relationships between changes in cardiovascular risk factors: the SOS Intervention Study. Obes Res 1997;5:519-30
7. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women.N Engl J Med 1995;333, 677-85
8. Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol 1997; 145:614-19
9. Laakso M, Uusitupa M, Takala J, et al. Effects of hypocaloric diet and insulin treatment on metabolic control and mechanisms of hyperglycemia in obese non-insulin dependent diabetic subjects. Metabolism 1988;37:1092-100
10. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulphonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128:165-75
11. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
12. Lean ME, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes mellitus. Diabet Med 1990;7:228-33
13. Wing RR, Koeske R, Epstein LH, et al. Long term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987;147:1749-53
14. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994;74:761-811
15. Spiegelmann BM. PPAR: adipogenic regulator and thiazol-idinedione receptor. Diabetes 1998;47:515-22
16. Kletzien R, Clarke S, Ulrich R. Enhancement of adipocyte differentiation by an insulin sensitizing agent. Mol Pharmacol 1992;41:393-8
17. Hanefeld M, Weck M. Very low calorie diet therapy in obese non-insulin dependent diabetic patients. Int J Obes 1989;13:33-7
18. Wilding J, Williams G. Diabetes and obesity. In Kopelman PG, ed. Clinical Obesity, Oxford: Blackwell Science, 1998
19. Henry R, Gumbiner B. Benefits and limitations of very low calorie diet therapy in obese NIDDM. Diabetes Care 1991; 14:802-23
20. Garg A. High-monounsaturated-fat diets for patients with diabetes mellitus: a metaanalysis. Am J Clin Nutr 1998;67: 577-82S
21. Schneider SH, Khachadurian AK, Amorosa LF, et al. Ten year experience with an exercise based outpatient life-style modification program in the treatment of diabetes mellitus. Diabetes Care 1992;15:1800-10
22. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997;21 (Suppl 3):S12-23
23. McNeely W, Benfield P. Orlistat. Drugs 1998;56:241-9
24. Sjostrom L, Rissanen A, Andersen T, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352:167-73
25. Taylor T. The effect of orlistat on glucose tolerance in obese nondiabetic individuals. Diabetologia 1997;40(Suppl 1): A197, P773
26. Robbins DC. Development of diabetes mellitus (DM) and IGT among obese: the orlistat studies. Diabetes 1998;47 (Suppl 1):A93, O362
27. Rissanen A. Orlistat-induced weight loss improves response to oral glucose tolerance testing. Int J Obes Rel Met Disord 1998;22 (Suppl 3):S274, P677
28. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1 year randomized double blind study. Diabetes Care 1998;21:1288-94
29. Lean MEJ. Sibutramine-a review of clinical efficacy. Int J Obes Rel Metab Disord 1997;27 (Suppl):S30-S36
30. Fujioka K, Weinstein SP, Rowe E. Sibutramine induces weight loss and improves glycaemic control in obese patients with type 2 diabetes mellitus. Diabetologia 1998; 41 (Suppl 1):A215:832
31. Heath MJ, Chong E, Weinstein SP, Seaton TB. Sibut-ramine enhances weight loss and improves glycaemic control and plasma lipid profile in obese patients with type 2 diabetes mellitus. Diabetes 1999;48 (Suppl 1):A 308
32. Van Gaal LF, and the STORM study group. Sibutramine trial of obesity reduction and maintenance. Effects on risk factors. Int J Obes Relat Disord 1998;22 (Suppl 3): S272, P668
33. Uusitupa MJ, Laakso M, Sarlund H, et al. Effects of a very low calorie diet on metabolic control and cardiovascular risk factors in the treatment of obese non-insulin dependent diabetics. Am J Clin Nutr 1990;51:768-73
34. James WPT, Astrup A, Finer N, et al., for the STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356:2119-25